文献速递白血病造血干细胞移植与细胞治疗

间充质基质细胞来源的囊泡货物对B细胞急性淋巴细胞白血病进展的影响

Impact of mesenchymal stromal cell-derived vesicular cargo on B-cell acute lymphoblastic leukemia progression.
PubMed 文献 · Blood Adv · 2023-01-01

该研究显示骨髓微环境中间充质基质细胞PLEKHM1缺失可通过改变小细胞外囊泡货物(syntenin和syndecan-1增加)加速小鼠BCR-ABL1阳性B细胞急性淋巴细胞白血病进展,并增强白血病起始细胞的数量和功能;炎症因子可下调间充质基质细胞PLEKHM1,形成循环;人B-ALL骨髓活检中PLEKHM1阳性间充质基质细胞比例降低。

要点

  • 间充质基质细胞PLEKHM1缺失加速小鼠BCR-ABL1阳性B-ALL进展。
  • PLEKHM1缺失的间充质基质细胞及其小细胞外囊泡携带更多syntenin和syndecan-1。
  • 炎症因子可下调间充质基质细胞PLEKHM1并增加syntenin和syndecan-1。

核心结论

  • 骨髓微环境来源的小细胞外囊泡在驱动BCR-ABL1阳性B-ALL中起重要作用,可能贡献于其较BCR-ABL1阴性B-ALL更差的预后。
  • 作者认为癌细胞分泌炎症因子可能普遍调节肿瘤微环境。

研究设计与样本

  • 研究采用小鼠BCR-ABL1阳性B-ALL模型及体外实验,涉及间充质基质细胞PLEKHM1缺失、小细胞外囊泡处理白血病起始细胞以及人B-ALL骨髓活检分析。

主要发现

  • PLEKHM1缺失的间充质基质细胞及其小细胞外囊泡携带增加的syntenin和syndecan-1,通过黏着斑激酶和AKT信号导致更不成熟的B细胞表型及白血病起始细胞数量和功能增加。
  • 用PLEKHM1缺失间充质基质细胞来源的小细胞外囊泡体外预处理白血病起始细胞,强烈倾向于加速小鼠和人BCR-ABL1阳性B-ALL。
  • 重组或B-ALL细胞来源的肿瘤坏死因子α或白细胞介素-1β在体外作用于小鼠和人间充质基质细胞,降低PLEKHM1并增加syntenin和syndecan-1。
  • 人B-ALL患者骨髓活检显示PLEKHM1阳性间充质基质细胞比例降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemia cells reciprocally interact with their surrounding bone marrow microenvironment (BMM), rendering it hospitable to leukemia cell survival, for instance through the release of small extracellular vesicles (sEVs). In contrast, we show here that BMM deficiency of pleckstrin homology domain family M member 1 (PLEKHM1), which serves as a hub between fusion and secretion of intracellular vesicles and is important for vesicular secretion in osteoclasts, accelerates murine BCR-ABL1+ B-cell acute lymphoblastic leukemia (B-ALL) via regulation of the cargo of sEVs released by BMM-derived mesenchymal stromal cells (MSCs). PLEKHM1-deficient MSCs and their sEVs carry increased amounts of syntenin and syndecan-1, resulting in a more immature B-cell phenotype and an increased number/function of leukemia-initiating cells (LICs) via focal adhesion kinase and AKT signaling in B-ALL cells. Ex vivo pretreatment of LICs with sEVs derived from PLEKHM1-deficient MSCs led to a strong trend toward acceleration of murine and human BCR-ABL1+ B-ALL. In turn, inflammatory mediators such as recombinant or B-ALL cell-derived tumor necrosis factor α or interleukin-1β condition murine and human MSCs in vitro, decreasing PLEKHM1, while increasing syntenin and syndecan-1 in MSCs, thereby perpetuating the sEV-associated circuit. Consistently, human trephine biopsies of patients with B-ALL showed a reduced percentage of PLEKHM1+ MSCs. In summary, our data reveal an important role of BMM-derived sEVs for driving specifically BCR-ABL1+ B-ALL, possibly contributing to its worse prognosis compared with BCR-ABL1- B-ALL, and suggest that secretion of inflammatory cytokines by cancer cells in general may similarly modulate the tumor microenvironment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karantanou C, Minciacchi VR, Kumar R, et al. Impact of mesenchymal stromal cell-derived vesicular cargo on B-cell acute lymphoblastic leukemia progression. Blood Adv. 2023. PMID: 36044386. doi:10.1182/bloodadvances.2022007528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。